<DOC>
	<DOCNO>NCT01708564</DOCNO>
	<brief_summary>This study ass pharmacokinetics pharmacodynamics rhFVIIa three dose level . The result help identify optimal dos take forward Phase 2/3 study bleeding hemophilia patient inhibitor treat rhFVIIa .</brief_summary>
	<brief_title>A Phase I Safety , Pharmacokinetics Pharmacodynamics Study Recombinant Factor VIIa Adult Patients With Hemophilia A B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1. male diagnosis moderate severe congenital hemophilia A and/or B ( without inhibitor ) 2. 18 year old , include 75 year age 3. capable understand willing comply condition protocol 4. read , understood provide write informed consent 1. coagulation disorder hemophilia A B 2. body weight &gt; 105 kg ( 231 lb ) 3. immunosuppressed ( i.e. , patient receive systemic immunosuppressive medication &lt; 30 day prior enrollment , CD4 count screen &gt; 200/Âµl ) 4. know allergy hypersensitivity rabbit 5. platelet count &lt; 100,000/mL 6. within one month prior first administration study drug study major surgical procedure ( e.g . orthopedic , abdominal ) 7. active , ongoing bleed patient treat , treatment bleeding stop within 24 hour time study drug administration 8. receive Factor VII FVIIa contain product ( either plasma derive recombinant ) within 72 hour prior study drug administration 9. receive investigational drug within 30 day first study drug administration , expect receive drug participation study 10. clinically relevant hepatic ( hepatic enzyme &gt; 3 time upper limit normal ) and/or renal impairment ( creatinine &gt; 2 time upper limit normal ) 11. history arterial and/or venous thromboembolic event ( myocardial infarction , ischemic stroke , transient ischemic attack , deep venous thrombosis pulmonary embolism ) within 2 year prior first dose study drug , arterial stent place clinically significant atherosclerotic disease ( e.g. , angina pectoris , peripheral vascular disease ) 12. use anticoagulant arterial/venous obstruction and/or atrial fibrillation within 7 day prior first study drug administration 13. active malignancy ( nonmelanoma skin cancer allow ) 14. lifethreatening disease disease condition , accord investigator 's judgment , could imply potential hazard patient , interfere trial participation trial outcome</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>